SynthesisFrontiers in pharmacology2025
Large extracellular vesicles (microvesicles) in diabetic nephropathy: a systematic review of preclinical studies.
Synthesis in Frontiers in pharmacology, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
4 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Diabetic nephropathy (DN) is a significant complication of diabetes and is characterized by progressive kidney damage and dysfunction. Several studies have highlighted the role of a subset of large-sized extracellular vesicles (EVs), commonly known as microvesicles (MVs), as crucial mediators of DN pathophysiology. This systematic review critically evaluates the methodological approaches used to study MVs in experimental models of DN, while also synthesizing the experimental endpoints investigated, to identify consistencies, gaps, and opportunities for standardization. A systematic literature search across PubMed, Embase, and Scopus identified preclinical studies investigating the impact of MVs on renal injury, inflammation, and fibrosis in diabetes. Seven preclinical studies published between 2014 and 2022 met the inclusion criteria. Data extracted: MV origin, isolation/characterization/quantification, models/conditions, dosing/exposure, and endpoints. Seven studies (2014-2022) met criteria. Differential centrifugation predominated for isolation; flow cytometry (FCM) (often Annexin V ± lineage markers), nanoparticle tracking analysis (NTA), and electron microscopy (EM) variably supported identity/size; FCM and NTA were commonly used for enumeration along with protein assays. MV sources included platelets, podocytes, urinary fractions, and MSC-derived vesicles. Across studies, MVs modulated oxidative stress (NOX4/ROS), inflammation (e.g., TNF-α, CXCL7), fibrotic signaling (p38 MAPK/CD36), and cell injury; cargo (e.g., miR-451a) linked to cell-cycle regulators (p15/p19) in early DN. Notable heterogeneity in media depletion, dose reporting, and detection thresholds limited cross-study comparison. We conclude that preclinical evidence supports MVs as early biomarkers and mechanistic drivers in DN, but standardization in isolation, characterization, dosing, and endpoint panels-aligned with MISEV 2023-is needed to enable comparability and translation.
Indexed as
Identifiers
What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.